Alamar Biosciences closes IPO of 12.9M shares at $17.00, raising ~$219.9M

Alamar Biosciences, Inc.

Completed IPO of 12,937,500 shares of common stock at $17.00 per share, including full exercise of underwriters' option for 1,687,500 shares.
Aggross gross proceeds of approximately $219.9 million before underwriting discounts and offering expenses.
Amended and restated certificate of incorporation and bylaws became effective immediately prior to IPO closing.
Shares now trade on Nasdaq under ticker 'ALMR'.

item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alamar Biosciences, Inc.: Adopted amended and restated bylaws effective April 20, 2026 (effective 2026-04-20).

Change: bylaw amendment
Effective: 2026-04-20

Exact text from the filing

Effective as of April 20, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alamar Biosciences, Inc.: Filed amended and restated certificate of incorporation effective as of immediately prior to the closing of the IPO on April 20, 2026 (effective 2026-04-20).

Change: charter amendment
Effective: 2026-04-20

Exact text from the filing

the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.

View on SEC.gov

Browse all governance changes →

Alamar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-163921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.